EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of human cytomegalovirus replication by valaciclovir

Blair L Strang

Journal of General Virology · 2025

DOI: 10.1099/jgv.0.002178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of General Virology, 2025. Verfasst von Blair L Strang. Beteiligte Einrichtung: Institute of Infection & Immunity, St George's School of Health and Medical Sciences, City St George's, University of London, London, UK. Hauptthemen laut MEDLINE: Antiviral Agents, Virus Replication, Cytomegalovirus, Acyclovir. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: St. George's, University of London.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vertical transmission of human cytomegalovirus (HCMV) during pregnancy is a major cause of congenital disease. In the absence of robust vaccination strategies, antiviral drug regimens are being developed to inhibit the vertical transmission of the virus. Recent clinical data have indicated that valaciclovir, an orally bioavailable form of aciclovir, was effective at limiting vertical transmission of HCMV when administered during pregnancy. However, there is no widely cited in vitro analysis of valaciclovir’s antiviral effect against HCMV, and it is possible, like aciclovir, that valaciclovir has poor anti-HCMV activity. The antiviral effects of aciclovir and valaciclovir against HCMV were compared to the widely used anti-HCMV drug ganciclovir. Compared to ganciclovir, the anti-HCMV effects of either aciclovir or valaciclovir were poor, and robust anti-HCMV activity in all cell lines tested (adult fibroblast, foetal fibroblast or trophoblast cells) was only observed at high drug concentrations. All drugs had no obvious effects on the viability of uninfected cells. Overall, valaciclovir had poor anti-HCMV activity, and its anti-HCMV efficacy upon administration during pregnancy may rely on a combination of factors. These data argue for the continued development of valaciclovir and anti-HCMV compounds to inhibit vertical virus transmission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsVirus ReplicationCytomegalovirusAcyclovirValineHumansValacyclovirPregnancyCell LineFemaleGanciclovirCytomegalovirus InfectionsFibroblastsInfectious Disease Transmission, Vertical

Stichwörter der Autor:innen

cytomegalovirusdrugpregnancyvalaciclovir

Substanzen

Antiviral AgentsValacyclovirAcyclovirValineGanciclovir

Autor:innen und Institutionen

  • Institute of Infection & Immunity, St George's School of Health and Medical Sciences, City St George's, University of London, London, UK.

Förderung

  • St. George's, University of London

Zitieren

APA

Strang, B. L. (2025). Inhibition of human cytomegalovirus replication by valaciclovir. Journal of General Virology. https://doi.org/10.1099/jgv.0.002178

Vancouver

Strang BL. Inhibition of human cytomegalovirus replication by valaciclovir. Journal of General Virology. 2025. doi:10.1099/jgv.0.002178

BibTeX
@article{Strang2025,
  author = {Strang, Blair L},
  title = {Inhibition of human cytomegalovirus replication by valaciclovir},
  journal = {Journal of General Virology},
  year = {2025},
  doi = {10.1099/jgv.0.002178}
}
Kostenlos starten →